KIF3A

Across TCGA pan-cancer cohorts, KIF3A mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of KIF3A’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where KIF3A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types KIF3A is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

HNSC, LUAD, and COAD are the cancer types where KIF3A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KIF3A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+0.223	<.001	8	view →
LUAD	Male	II,III,IV	+0.210	<.001	7	view →
COAD	Female	II,III,IV	+0.244	<.001	6	view →
LSCC	Male	II,III,IV	+0.103	.007	5	view →
CCRCC	Male	III,IV	+0.139	.003	4	view →
PDAC	Male	All	−0.201	.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

KIF3A–HNSC

Open the HNSC breakdown →